Anyone searching for a Semax dosage is usually after a specific amount. The evidence-based position is that there is no MHRA-, EMA- or FDA-approved dose for Semax. Semax is, however, a registered medicine in Russia, supplied there as defined intranasal solutions, and most human research on it is Russian and uses that intranasal route. There are no Western Phase 2/3 trials. This article documents what has actually been investigated and how it was administered — it is a review of published research and registrations, not a recommendation.
What is Semax?
Semax is a synthetic heptapeptide based on the 4–10 fragment of the hormone ACTH, with a C-terminal proline-glycine-proline tail added to slow enzymatic breakdown. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow in the 1980s and has been studied as a neuroprotective and cognition-related peptide, including effects on brain-derived neurotrophic factor (BDNF). Semax is not approved by the MHRA, EMA or FDA and is supplied strictly as a laboratory research reagent.
Is there an established Semax dosage?
This needs a careful distinction:
- In Russia, Semax is a registered medicine available as intranasal solutions — commonly a 0.1% formulation and a stronger 1% formulation — with approved indications that have included cognitive/encephalopathy conditions, ischaemic stroke recovery and certain optic-nerve conditions.
- In the UK, EU and US, there is no approval and no established dose, and no Western Phase 2/3 clinical trial programme.
A registration in one country is not a global recommendation, and the Russian formulations are described by concentration and course rather than as guidance for personal use.
Semax dosage investigated in human clinical research
Human research is predominantly Russian and intranasal:
| Setting | Model | Formulation / route | Reported focus |
|---|---|---|---|
| Acute ischaemic stroke (Gusev, Skvortsova et al.) | Russian clinical trials | 0.1% intranasal Semax vs placebo, given as fixed courses alongside standard care | Neurological deficit (e.g. NIHSS), recovery outcomes |
| Registered clinical use (Russia) | Patients | 0.1% and 1% intranasal solutions | Cognitive/encephalopathy, stroke recovery, optic-nerve conditions |
Russian stroke research administered intranasal Semax in defined treatment courses. The exact milligram-per-day amounts vary between Russian protocols and are documented in the original, largely Russian-language publications; because those precise figures cannot be uniformly verified from primary English-language sources, they are not stated here as guidance. What can be stated reliably is the route (intranasal) and the registered concentrations (0.1% and 1%).
Dose-escalation research
There is no published Western dose-escalation programme for Semax (a designed low-to-high comparison with defined arms and regulated endpoints). Russian clinical use is structured around fixed formulations (0.1% vs 1%) and set treatment courses rather than a formal escalation study. This is reported as historical/registration structure, not as a titration scheme.
Preclinical (animal and laboratory) research
Semax has an extensive preclinical literature, largely in rodents, studying neuroprotection, learning and neurotrophic signalling (including BDNF and NGF pathways) in models of ischaemia and cognition. These studies dose Semax by body weight or per animal (for example microgram-per-kilogram amounts, intranasally or by injection in rodents).
These are preclinical findings and cannot be interpreted as establishing an equivalent human dosage. Rodent amounts are tied to species, weight and route and cannot be converted into a human dose.
What did different dosage groups show?
The clearest human comparison is between the two registered concentrations — the 0.1% formulation used more broadly and the stronger 1% formulation used in stroke settings — but this reflects product strength and indication rather than a controlled dose–response trial. No Western-standard, multi-arm human dose–response dataset for Semax has been published.
Safety and adverse events reported in research
In Russian clinical use, intranasal Semax has generally been described as well tolerated, with few reported adverse effects. However, controlled Western safety data — the kind generated by MHRA/EMA/FDA-standard trials — does not exist, so the long-term and comparative safety picture is not established to that standard. Absence of reported problems in a limited literature is not the same as demonstrated safety.
What the research does not tell us
- It does not provide an MHRA/EMA/FDA-approved dose — Semax has none.
- Russian registration and Russian-language trial data are not equivalent to Western Phase 2/3 evidence.
- Precise per-day milligram amounts vary by protocol and could not be uniformly verified from primary English-language sources.
- Rodent amounts cannot be converted into a human dose.
- There is no controlled long-term Western safety dataset.
Semax research timeline
- 1980s — Semax developed at the Institute of Molecular Genetics, Russian Academy of Sciences, Moscow.
- 1990s–2000s — Registered as a medicine in Russia; Russian clinical research evaluates intranasal Semax in ischaemic stroke and cognitive conditions.
- Ongoing — No MHRA/EMA/FDA approval and no Western Phase 2/3 programme; remains a research reagent outside Russia.
Key takeaway
Semax is a Russian-registered intranasal medicine (0.1% and 1% solutions) studied mainly in Russian clinical research for stroke and cognitive conditions, with an extensive rodent preclinical literature. It has no approval from the MHRA, EMA or FDA, no Western Phase 2/3 trials, and precise per-day amounts vary by protocol. The formulations and study details above describe research and registrations — not a personal dosing recommendation.
References
- Gusev EI, Skvortsova VI, et al. Clinical research on intranasal Semax (0.1%) in acute ischaemic stroke. PubMed: PMID 17395875.
- Institute of Molecular Genetics, Russian Academy of Sciences — origin of Semax (ACTH(4–10) analogue); background summarised in peptide neuropharmacology reviews indexed on PubMed (Semax).